Literature DB >> 25609156

Bisphosphonate therapy: how long is long enough?

M R McClung1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25609156     DOI： 10.1007/s00198-014-3019-4

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  24 in total

1.  Effect of stopping risedronate after long-term treatment on bone turnover.

Authors:  Richard Eastell; Rosemary A Hannon; Dietrich Wenderoth; Jesus Rodriguez-Moreno; Andrzej Sawicki
Journal:  J Clin Endocrinol Metab       Date:  2011-08-24       Impact factor: 5.958

2.  Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA).

Authors:  O Ström; E Landfeldt; G Garellick
Journal:  Osteoporos Int       Date:  2014-10-09       Impact factor: 4.507

3.  Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women.

Authors:  J L Stock; N H Bell; C H Chesnut; K E Ensrud; H K Genant; S T Harris; M R McClung; F R Singer; R A Yood; S Pryor-Tillotson; L Wei; A C Santora
Journal:  Am J Med       Date:  1997-10       Impact factor: 4.965

4.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Authors:  S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller
Journal:  JAMA       Date:  1999-10-13       Impact factor: 56.272

5.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

Review 6.  Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.

Authors:  Michael McClung; Steven T Harris; Paul D Miller; Douglas C Bauer; K Shawn Davison; Larry Dian; David A Hanley; David L Kendler; Chui Kin Yuen; E Michael Lewiecki
Journal:  Am J Med       Date:  2012-11-20       Impact factor: 4.965

7.  Fracture risk remains reduced one year after discontinuation of risedronate.

Authors:  N B Watts; A Chines; W P Olszynski; C D McKeever; M R McClung; X Zhou; A Grauer
Journal:  Osteoporos Int       Date:  2007-10-16       Impact factor: 4.507

8.  Changes in bone density and turnover after alendronate or estrogen withdrawal.

Authors:  Richard D Wasnich; Yu Z Bagger; David J Hosking; Michael R McClung; Mei Wu; Ann Marie Mantz; John J Yates; Philip D Ross; Peter Alexandersen; Pernille Ravn; Claus Christiansen; Arthur C Santora
Journal:  Menopause       Date:  2004 Nov-Dec       Impact factor: 2.953

9.  The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

Authors:  Dennis M Black; Ian R Reid; Steven Boonen; Christina Bucci-Rechtweg; Jane A Cauley; Felicia Cosman; Steven R Cummings; Trisha F Hue; Kurt Lippuner; Peter Lakatos; Ping Chung Leung; Zulema Man; Ruvie Lou Maria Martinez; Monique Tan; Mary Ellen Ruzycky; Guoqin Su; Richard Eastell
Journal:  J Bone Miner Res       Date:  2012-02       Impact factor: 6.741

10.  Persistence with weekly and monthly bisphosphonates among postmenopausal women: analysis of a US pharmacy claims administrative database.

Authors:  Tao Fan; Qiaoyi Zhang; Shuvayu S Sen
Journal:  Clinicoecon Outcomes Res       Date:  2013-11-19
View more
  3 in total

1.  Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.

Authors:  K E Naylor; M Bradburn; M A Paggiosi; F Gossiel; N F A Peel; E V McCloskey; J S Walsh; R Eastell
Journal:  Osteoporos Int       Date:  2018-03-10       Impact factor: 4.507

Review 2.  [Current prevention and treatment strategies for osteoporosis. Fracture-oriented, effective, low side effects and inexpensive].

Authors:  R Bartl; C Bartl
Journal:  Internist (Berl)       Date:  2015-12       Impact factor: 0.743

3.  Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab.

Authors:  Alexander Wick; Philipp Bankosegger; Sven Otto; Bettina Hohlweg-Majert; Timm Steiner; Florian Probst; Oliver Ristow; Christoph Pautke
Journal:  Clin Oral Investig       Date:  2021-11-23       Impact factor: 3.573
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.